Answers are grounded in this paper and cite their sources.
Testicular cancer is the most common cause of cancer in the U.S. male active duty population. Advancements in surgical and chemotherapy approaches have led to a 95% 5-year survival rate across all stages. The United States Preventive Services Task Force recommends against non-symptomatic clinical screening or patient self-examination citing the high survival rate and overall low civilian incidence. We present 2 case reports of active duty individuals who died from complications of testicular cancer. Case 1 was found deceased. At autopsy, a pelvic mass was found disrupting the aorta along with hemoperitoneum. The mass was subsequently identified as a metastatic mixed germ cell tumor. Case 2 presented with orchalgia and a testicular mass, but did not attend to his ordered ultrasound before deployment. He returned to the United States with a >10 cm testis, widespread metastatic disease, and a serum beta-human chorionic gonadotropin (hCG) over 250,000. A non-seminomatous germ cell tumor was presumed, and an orchiectomy was delayed to initiate chemotherapy. He died shortly after therapy was initiated from a pulmonary hemorrhage. In this article, we discuss how unique features of the military population may impact testicular cancer care with evidence from these 2 cases along with suggestions where impactful change can be made.
No takes yet. Share an insight, caveat, or question.
Canevari et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: